We wondered about the prediction efficacy that RUNX3/H3K27me3 co-expression might have on these populations and found that no survival difference had been determined in POCT patients (P=0.3820, Figure 10(a)) based on the different status of RUNX3/H3K27me3 co-expression, while in non-POCT patients (P=0.0029, Figure 10(b)), this difference was obvious, and non-POCT NSCLC patients with RUNX3/H3K27me3 co-expression demonstrated a better prognosis, and this situation was ever true in pTNM-I (P=0.0456, Figure 10(c)) and non-pTNM-I (P=0.0244, Figure 10(d)) patients. The gene discussed is RUNX3; the disease is non-small cell lung carcinoma.